Welcome to our dedicated page for Onco-Innovations news (Ticker: ONNVF), a resource for investors and traders seeking the latest updates and insights on Onco-Innovations stock.
News for Onco-Innovations Limited (ONNVF) centers on its activities in oncology research, preclinical drug development, AI-enabled precision medicine, and corporate financing. The company describes itself as a Canadian-based oncology-focused organization with an exclusive worldwide license to patented technology targeting solid tumours, including its PNKP Inhibitor Technology platform.
Investors and observers following Onco-Innovations’ news can expect updates on the advancement of its PNKP Inhibitor Technology (A83B4C63), including manufacturing milestones with Dalton Pharma Services such as process optimization, intermediate scale-up, analytical method development, and preparation for potential future clinical material production. Releases also cover collaborations with partners like Kuano Ltd., where quantum-ready molecular modelling and AI-driven compound design are being applied to deepen understanding of PNKP inhibition and guide next-generation therapeutic candidates.
Another important stream of news involves Onco-Innovations’ subsidiary Inka Health and its SynoGraph platform. Announcements have highlighted publications on the transportability of real-world evidence, integration of advanced statistical methods into SynoGraph, and participation in precision oncology forums with organizations such as Colorectal Cancer Canada. These items illustrate how the company links AI, real-world data, and oncology decision-making.
Corporate and capital markets developments also feature in the news flow. Onco-Innovations has reported private placements, board appointments, marketing engagements, and its intention to pursue a potential Nasdaq cross-listing with the support of a U.S. investment bank. For a consolidated view of these scientific, strategic, and financing updates, this news page provides a single location to review the company’s disclosed developments over time.
Onco-Innovations Limited (CSE:ONCO) has announced the transfer of its common shares listing from the Canadian Securities Exchange (CSE) to Cboe Canada Inc. The transition will take effect on May 22, 2025, with the company maintaining its existing ticker symbol \"ONCO\". The voluntary delisting from CSE is scheduled for May 21, 2025.
Cboe Canada, a Tier 1 stock exchange within the global Cboe Markets network, provides advanced market infrastructure and real-time data solutions, including its ETF Market Canada platform that analyzes over 1,200 Canadian ETFs. CEO Thomas O'Shaughnessy emphasized that this strategic move aims to enhance the company's visibility in capital markets, broaden its investor base, and strengthen institutional engagement.
Onco-Innovations (OTCQB:ONNVF) has announced that its subsidiary Inka Health has secured a new analytical work contract with AstraZeneca Canada on March 20, 2025. The contract focuses on advancing real-world evidence (RWE) research in regulatory science.
Under the new agreement, Inka Health will develop a peer-reviewed scientific manuscript examining how international RWE is utilized in submissions to Canada's Drug Agency (CDA). This project expands on previous collaborative work that addressed bias and generalizability challenges in non-local RWE, which has been accepted for presentation at ISPOR 2025 (May 11-15, 2025).
The renewed engagement demonstrates AstraZeneca's confidence in Inka Health's capabilities to support drug evaluation, submission strategies, and evidence planning within Canada's regulatory framework.
Onco-Innovations (OTCQB:ONNVF) has announced the appointment of Dr. James Orbinski to its Scientific and Clinical Advisory Board. Dr. Orbinski, a former International President of Médecins Sans Frontières (MSF), is notable for accepting the Nobel Peace Prize on behalf of MSF in 1999.
Currently a Full Professor at Temerty School of Medicine and the University of Toronto, Dr. Orbinski brings extensive experience in global health and humanitarian medicine. He was the founding Director of the Dahdaleh Institute for Global Health Research and co-chaired MSF's Neglected Diseases Working Group. His work with the Drugs for Neglected Diseases Initiative (DNDi) has led to the development of 13 treatments for 6 deadly diseases since 2003.
An Officer of the Order of Canada and recipient of the Meritorious Service Cross, Dr. Orbinski will provide strategic insight for Onco's scientific programs and global oncology innovations.
Onco-Innovations (ONNVF) has partnered with Dalton Pharma Services for the custom synthesis of a heavy labelled isotope of its exclusively-licensed PNKP inhibitor technology. The agreement, dated April 8, 2025, aims to advance IND-enabling animal model research through ADME studies.
The technology's effectiveness was previously demonstrated in a June 2021 University of Alberta study using PTEN-deficient colorectal cancer xenograft mice. The study showed that mice treated with the nanoparticle-encapsulated A83B4C63 (PNKP Inhibitor) achieved a median survival time of 60 days, compared to 23 days in untreated controls.
The technology enhances PNKP inhibitors' effectiveness while reducing impact on healthy tissues. This partnership with Dalton represents a important step toward generating necessary data for regulatory submissions and advancing the program toward clinical trials.
Onco-Innovations (OTCQB:ONNVF) has announced a non-brokered private placement of up to 400,000 units at $1.50 per unit, aiming to raise gross proceeds of up to $600,000. Each unit includes one common share and one warrant, with each warrant allowing the purchase of one share at $1.60 for 36 months.
The private placement is expected to close around April 25, 2025, subject to regulatory approvals. Securities will have a four-month and one-day hold period. The company plans to use the proceeds for general corporate and working capital purposes, including operational and R&D objectives.
Onco-Innovations is a Canadian company focused on cancer research and treatment, holding an exclusive worldwide license for patented technology targeting solid tumors.
Onco-Innovations' (ONNVF) subsidiary Inka Health has published a groundbreaking study in JAMA Network Open, sponsored by Roche, addressing methodological gaps in real-world oncology research. The study, titled 'Quantitative Bias Analysis for the Assessment of Bias in Comparisons between Synthetic Control Arms,' introduces Q-BASEL, a novel approach to improve the validity of clinical comparisons from real-world data.
The research, led by Inka Health co-founder Alind Gupta, conducted 15 treatment comparisons in advanced non-small cell lung cancer (aNSCLC) using real-world patient data. The study demonstrated that applying Quantitative Bias Analysis (QBA) significantly improved the alignment between real-world emulations and original randomized trial outcomes.
This methodology will be integrated into Inka's SynoGraph platform, enhancing support for pharmaceutical partners in optimizing real-world evidence strategies, particularly in scenarios where traditional randomized trials are not feasible.
Onco-Innovations (OTCQB:ONNVF) announces its subsidiary Inka Health has completed analytical work for AstraZeneca Canada under a service agreement from September 2024. The project focuses on advancing pharmaceutical evidence generation and real-world data analysis.
Two research studies will be presented at ISPOR 2025 in Montréal: The first study explores methodologies to enhance real-world evidence credibility through transportability analyses, while the second evaluates RWE utilization in Canadian drug regulatory submissions.
The findings are being integrated into Inka Health's proprietary analytics platform, SynoGraph, which incorporates advanced causal inference techniques. The presentations are scheduled for May 16, 2025, from 9:00-11:30 AM ET at the conference.
Onco-Innovations (ONNVF) has reported positive results from a December 2021 University of Alberta study on its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound used in combination with radiation therapy. The study focused on mice with colorectal cancer tumors, divided into three treatment groups receiving different combinations of treatments over 24 days.
The key finding revealed that the PNKP technology demonstrated effective cancer cell targeting while maintaining a low toxicity profile, even at therapeutic doses. Notably, no significant toxicity signs, including weight loss, were observed in any treatment group, including those receiving PNKP inhibitor-loaded nanoparticles with radiation.
This development is particularly significant as it suggests potential for developing safer cancer treatments with fewer side effects. The technology's minimal toxicity in preclinical animal models aligns with Health Canada's rigorous testing requirements for drug safety assessment.
Onco-Innovations (OTCQB:ONNVF) has announced the extension of its marketing engagement with MCS Market Communication Service GmbH through May 31, 2025. The company has allocated CAD 600,000 for the extended services, which include campaign creation, marketing materials production, and research and analytics.
The marketing services will be delivered through digital channels, specifically Google Ads and native advertising. The agreement will continue until the specified end date or until the budget is exhausted. No securities were issued as compensation for these services.